Skip to Content

Proteostasis Therapeutics, Inc.

Merger

  • Date:
  • 8/24/2020
  • Company Name:
  • Proteostasis Therapeutics, Inc.
  • Stock Symbol:
  • PTI
  • Company Name - Buyer:
  • Yumanity Therapeutics
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/24/2020

Case Finder

Locate any case using the tools below.

NEW YORK, August 24, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Proteostasis Therapeutics, Inc. (NASDAQ: PTI) (“PTI”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Yumanity Therapeutics.

On August 24, 2020, PTI announced that it had signed an agreement to be acquired by Yumanity. At the close of the merger, members of PTI will collectively own approximately 32.5% of the new company, while former shareholders of Yumanity will own approximately 67.5% of the new company. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that PTI’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for PTI’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Proteostasis Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: